Literature DB >> 6095771

Pharmacokinetics of ketoconazole and treatment evaluation in candidal infections.

M Bardare, A M Tortorano, M C Pietrogrande, M A Viviani.   

Abstract

Twenty six children with candidiasis, aged between 5 months and 14 years, were treated with different formulations and regimens of ketoconazole. Fifteen children had alimentary tract candidiasis, two had oesophagitis, one had urinary tract candidiasis, two vaginitis, two septicaemia, one endo-ophthalmitis, and three had chronic pulmonary illness with persistence of Candida albicans in sputum. Daily drug doses ranged from 3 to 13 mg/kg and duration of treatment from seven days to 18 months. Pharmacokinetic studies in 22 of the children are reported. A total of 3 mg/kg/day given in three divided doses did not yield sufficiently high concentrations, which were achieved with a daily dose of 8 to 10 mg/kg. The effectiveness of treatment was proved by negative mycological tests (cultures or specific antibodies, or both) in 88%, by cure in 73%, and improvement in 11%. In three patients evaluation was not possible due to an insufficiently proved diagnosis. Nausea and pyrosis in four patients were the only side effects noted and no laboratory abnormalities were found. To achieve therapeutic concentrations of ketoconazole in children we suggest a daily dosage of 7 to 10 mg/kg in two or three divided doses.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6095771      PMCID: PMC1628834          DOI: 10.1136/adc.59.11.1068

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  9 in total

1.  Pharmacokinetics of ketoconazole in normal subjects.

Authors:  T K Daneshmend; D W Warnock; A Turner; C J Roberts
Journal:  J Antimicrob Chemother       Date:  1981-10       Impact factor: 5.790

Review 2.  Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections.

Authors:  R C Heel; R N Brogden; A Carmine; P A Morley; T M Speight; G S Avery
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

3.  Treatment of chronic mucocutaneous candidosis with ketoconazole: preliminary results of a controlled, double-blind clinical trial.

Authors:  C H Kirkpatrick; E A Petersen; D W Alling
Journal:  Rev Infect Dis       Date:  1980 Jul-Aug

4.  The influence of gastric acidity on the bio-availability of ketoconazole.

Authors:  J W Van Der Meer; J J Keuning; H W Scheijgrond; J Heykants; J Van Cutsem; J Brugmans
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

5.  Pharmacokinetics of ketoconazole in patients with neoplastic diseases.

Authors:  A W Maksymiuk; H B Levine; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

6.  Treatment of chronic mucocutaneous candidosis with ketoconazole: a study of 12 cases.

Authors:  R J Hay; R S Wells; Y M Clayton; H J Wingfield
Journal:  Rev Infect Dis       Date:  1980 Jul-Aug

7.  Chronic mucocutaneous candidosis and other superficial and systemic mycoses successfully treated with ketoconazole.

Authors:  E Drouhet; B Dupont
Journal:  Rev Infect Dis       Date:  1980 Jul-Aug

8.  Disposition of ketoconazole, an oral antifungal, in humans.

Authors:  C Brass; J N Galgiani; T F Blaschke; R Defelice; R A O'Reilly; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

9.  Pharmacology of ketoconazole suspension in infants and children.

Authors:  C M Ginsburg; G H McCracken; K Olsen
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

  9 in total
  3 in total

Review 1.  Antifungal agents in neonatal systemic candidiasis.

Authors:  J N van den Anker; N M van Popele; P J Sauer
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of ketoconazole.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

3.  Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics.

Authors:  Jeffry Adiwidjaja; Alan V Boddy; Andrew J McLachlan
Journal:  Front Pharmacol       Date:  2020-01-30       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.